1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,550 | 5,800 | 12:18 | |
| 5,500 | 5,700 | 12:15 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.09. | HENLIUS (02696): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.09. | HENLIUS (02696): (1) CHANGES IN NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR (2) APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHANGES IN ... | - | HKEx | ||
| 25.09. | Amberstone and Henlius agree to develop solid-tumour T-cell engagers | 2 | Pharmaceutical Technology | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 24.09. | China's Henlius carves out $440M T-cell engager deal with Amberstone | 1 | FierceBiotech | ||
| 24.09. | HENLIUS (02696): INTERIM REPORT 2026 | 1 | HKEx | ||
| 23.09. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - COLLABORATION AND LICENSE AGREEMENT WITH AMBERSTONE FOR TWO T CELL ENGAGER PRODUCTS | - | HKEx | ||
| 11.09. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR 120 MG (1.7 ML) PER VIAL STRENGTH OF BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ... | 2 | HKEx | ||
| 07.09. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE LIST OF ELIGIBLE SECURITIES OF HONG KONG STOCK CONNECT | 1 | HKEx | ||
| 25.08. | HENLIUS (02696): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 21.08. | Shanghai Henlius Biotech Inc. Announces Increase In H1 Bottom Line | 1 | RTTNews | ||
| 21.08. | Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC | 609 | PR Newswire | SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the... ► Artikel lesen | |
| 21.08. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF HANG SENG COMPOSITE INDEX | 1 | HKEx | ||
| 21.08. | HENLIUS (02696): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 AND CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | - | HKEx | ||
| 20.08. | Sandoz baut Biosimilar-Pipeline mit chinesischer Henlius weiter aus | 12 | transkript.de | ||
| 18.08. | Sandoz adds 10 biosimilars through $322m Henlius deal | 8 | pharmaphorum | ||
| 17.08. | Sandoz strikes $322M biosimilars deal with Shanghai Henlius | 9 | FiercePharma | ||
| 17.08. | Henlius, Sandoz Expand Oncology Biosimilars Partnership with mAbs, ADCs | 7 | Contract Pharma | ||
| 17.08. | Sandoz announces collaboration agreement with Shanghai Henlius Biotech | 9 | PMLiVE | ||
| 17.08. | Sandoz targets industry patent void with $322m Henlius deal | 8 | Pharmaceutical Technology | ||
| 17.08. | Sandoz-Aktie steigt nach 322-Millionen-Dollar-Deal mit Henlius | 18 | Investing.com Deutsch |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,150 | +5,44 % | EQS-WpÜG: Übernahmeangebot / Zielgesellschaft: Qiagen N.V.; Bieter: Crown NL Bidco B.V. | EQS-WpÜG: Crown NL Bidco B.V. / Übernahmeangebot
Übernahmeangebot / Zielgesellschaft: Qiagen N.V.; Bieter: Crown NL Bidco B.V.
21.10.2026 / 23:30 CET/CEST
Veröffentlichung einer... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | 0,00 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| ABSCI | 10,040 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,000 | -0,08 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| SUMMIT THERAPEUTICS | 15,825 | -0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| RAPPORT THERAPEUTICS | 25,060 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on pipeline potential | ||
| ARCUS BIOSCIENCES | 19,080 | -0,03 % | Arcus Biosciences prices $250M public offering at $17.50 per share | ||
| KYMERA THERAPEUTICS | 112,56 | -0,06 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,640 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |
Das Unternehmen SHANGHAI HENLIUS BIOTECH INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,250 Euro und damit +1,63 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.